Q. Is the current standard of care has changed in just one year? Docetaxel may now be considered in low volume and de novo disease together with an AR pathway inhibitor and radiation therapy indications should be extended not only to low volume but also to high-volume de novo disease?
A. Yes, there have been some significant updates in the treatment landscape for prostate cancer, particularly in the context of high-volume and de novo metastatic disease. Recent guidelines and studies suggest that combining docetaxel with an androgen receptor (AR) pathway inhibitor (like abiraterone, enzalutamide, or apalutamide) may offer substantial benefits even in patients with low-volume disease. Additionally, the use of radiation therapy has been extended beyond low-volume disease to also include patients with high-volume de novo metastatic disease.
This approach is based on evidence showing improved survival outcomes and better disease control when these therapies are used in combination. It reflects a more aggressive treatment strategy aimed at achieving better long-term outcomes for patients with metastatic prostate cancer. However, the specific treatment plan should always be tailored to the individual patient's condition and discussed with their oncologist.
Written by
Seasid
To view profiles and participate in discussions please or .
Interesting result using ChatGPT. May I suggest adding to your prompt? And add more detail? Like specific circumstances. The studies where this came from. ChatGPT knows!
I just put the most important part of Alicia Morgan and Karim Fizazi interview because otherwise it is to long and people could easily miss the most important part. That is why I made a Post about it.
Here is the link to the interview between Alicia Morgan and Karim Fizazi on which my ChatGPT question is based:
I realised that people are missing the most important part of the interview. It is not that I am more intelligent but rather the fact that in communication less is more, hence I came to the idea to create this post with the most important part of the message.
You could ask Chat GPT to list the studies on which his answer is based etc. but I believe Mr Fizazi is competent and we could believe him. We don't have to check his conclusions. Just to add that instead of just simply radiation I could say radiation to the primary. Radiation to the prostate just in case if it is not clear enough.
Ok, I asked more specific questions about radiation benefits to the primary tumour as you suggested:
Q. Could you please list the studies and results of each listed study on which you are based your answer.
A. Recent studies have indeed shown that combining docetaxel with androgen receptor (AR) pathway inhibitors and radiation therapy provides significant benefits in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), including both low-volume and high-volume disease.
1. **CHAARTED Study**: This study initially demonstrated that only patients with high-volume disease benefited from the addition of docetaxel to androgen deprivation therapy (ADT). High-volume disease was defined as the presence of visceral metastases or at least four bone metastases with at least one outside the vertebral bodies and pelvis [[❞]](jnm.snmjournals.org/content....
2. **STAMPEDE Trial**: Post hoc analysis suggested that the benefits of adding docetaxel might extend to patients irrespective of disease volume. This trial also supported the intensification of treatment with docetaxel alongside ADT to improve overall survival [[❞]](jnm.snmjournals.org/content....
3. **LATITUDE Trial**: Focused on patients with de novo mHSPC, this trial showed significant survival benefits with the addition of AR pathway inhibitors to ADT, despite including higher-risk patients [[❞]](jnm.snmjournals.org/content....
4. **ARASENS and PEACE-1 Trials**: These trials evaluated the addition of AR pathway inhibitors to the combination of ADT and docetaxel. Both trials showed a significant improvement in overall survival with triplet therapy compared to the standard combination of ADT and docetaxel. Specifically, ARASENS reported a hazard ratio of 0.68 (P < 0.001) favoring the triplet therapy, and PEACE-1 showed a hazard ratio of 0.82 (P = 0.030) [[❞]](jnm.snmjournals.org/content... [[❞]](mdpi.com/1718-7729/29/12/747).
These studies collectively suggest that a more aggressive treatment strategy involving the combination of docetaxel, AR pathway inhibitors, and radiation therapy can offer better outcomes for patients with both low-volume and high-volume metastatic prostate cancer. This approach represents a significant shift in the standard of care, aiming to improve long-term survival and disease control [[❞]](jnm.snmjournals.org/content... [[❞]](mdpi.com/1718-7729/29/12/747).
Q. Which particular study concluded that radiation therapy to the primary is beneficial in both low and also high volume de novo metastatic hormone sensitive cancer?
A. Recent studies have provided insights into the role of radiation therapy for both low- and high-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC).
1. **STAMPEDE Trial**: This study indicated that adding radiation therapy to the primary tumor in men with newly diagnosed metastatic prostate cancer resulted in improved survival for patients with low-volume disease, but not for those with high-volume disease. However, subsequent analyses and additional data have begun to suggest potential benefits for certain high-volume cases as well [[❞]](urotoday.com/library-resour... [[❞]](urotoday.com/conference-hig....
2. **HORRAD Trial**: This trial evaluated the effect of prostate radiotherapy in metastatic prostate cancer and suggested that while there was no significant benefit for the overall population, subgroup analyses indicated potential benefits in patients with low-volume disease. Again, further insights have proposed reevaluating high-volume cases [[❞]](urotoday.com/library-resour....
3. **PEACE-1 Trial**: Although primarily focused on the addition of abiraterone to standard therapy, this trial also provided data on the benefits of combining local radiotherapy with systemic treatments, indicating potential survival benefits in various patient subgroups [[❞]](urotoday.com/library-resour....
These studies collectively support a nuanced approach where radiation therapy is considered for both low- and potentially high-volume de novo metastatic hormone-sensitive prostate cancer under specific circumstances, particularly when combined with systemic therapies like androgen receptor pathway inhibitors.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Progressing metastatic prostate cancer
Anyone with metastatic prostate cancer who has refused Androgen Deprivation Treatment?
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
ADT + Abi + Docetaxel for metastatic prostate cancer?
Revisiting Intermittent Therapy in Metastatic Prostate Cancer
